Frontier IP to host Portfolio Demo Day

RNS Number : 6710I
Frontier IP Group plc
06 December 2022
 

Reach - a non-regulatory announcement

AIM: FIPP

06 December 2022

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Frontier IP to host Portfolio Demo Day at the Imperial War Museum, Duxford Cambridge

 

 

Frontier IP, a specialist in commercialising intellectual property, is holding a Portfolio Demo Day at the Imperial War Museum, Duxford, Cambridge ("IWM Duxford" or the "Museum") on the afternoon and evening of Tuesday 6th December 2022.

 

The event is an opportunity for some of Frontier IP's portfolio companies to present, demonstrate and discuss their new technologies to help tackle fundamental challenges, such as climate, energy, food, water and health.

 

Guests include investors, representatives of companies supported by Frontier IP, and industry partners. An afternoon session in the Museum's Marshall Auditorium will consist of presentations from portfolio companies, while the evening reception will give them the opportunity to showcase their technology. No new material information will be disclosed.

 

The portfolio companies presenting and demonstrating technologies are:

 

· Cambridge Raman Imaging is using graphene-based ultra-fast lasers and artificial intelligence in next generation Raman-imaging microscopes to research, diagnose and monitor diseases, such as cancers

 

· CamGraPhIC is developing graphene-based photonics with the potential to make data and telecommunications transmission much faster while using less energy

 

· Elute is showcasing its use of forensic linguistic algorithms for high-speed search and comparison of unstructured document datasets

 

· Celerum is demonstrating its novel artificial intelligence based on meta-heuristics, including nature-inspired computing, to make logistics more efficient, supporting efforts to improve the industry's carbon efficiency

 

· Nandi Proteins is discussing its customised ingredients based on vegetable and animal proteins. These can be used to replace undesirable ingredients such as fat, gluten and E-number additives in processed foods, or those that people do not want to consume - for example replacing animal proteins with vegetable proteins

 

· The Vaccine Group is developing novel herpesvirus-based vaccine platforms. Projects include those to tackle Lassa fever, African Swine Fever, Streptococcus suis and Porcine Reproductive and Respiratory Syndrome in animals, and COVID-19 in humans

 

· Pulsiv will be showing its patented technology to significantly improve the energy efficiency of power supplies, battery chargers, and LED lighting. It also extracts much more energy from photovoltaic solar cells, improving their output

 

· Alusid is creating premium-quality tiles and architectural surfaces from industrial waste.

 

· Des Solutio is developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal healthcare and other products

 

· InSignals Neurotech is showing its patented technology to aid deep brain surgery on patients suffering neurological diseases, such as Parkinson's disease

 

· AquaInSilico is presenting its sophisticated software tools to optimise wastewater treatment, with potential applications spanning many different industries. It is a UN Ocean Innovator, working on a project to help protect and conserve one of the world's most diverse marine environments around the Cape Verde archipelago

 

· Liquid Graphene is a new spin-out company looking to exploit graphene-based inks to reduce the cost of solar cell manufacture and use

 

 

Frontier IP Chief Executive Officer Neil Crabb said: "We are looking forward to demonstrating the exciting technologies being developed by our portfolio companies and the role they have to play in helping to meet some of the serious challenges posed by climate change, water, food and energy."

 

 

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications and investor relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

 

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

 

 

T: 0203 328 5656

 

 

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAVELFBLLLXFBB
UK 100

Latest directors dealings